CL2016000363A1 - Diacuerpos monovalentes biespecificos que pueden unirse a gpa33 y cd3, y pueden tener un dominio a albumina adicional o un dominio fc adicional; polinucleotido que los codifica; celula huesped; composicion farmaceutica que los comprende; y sus usos para tratar cancer. - Google Patents

Diacuerpos monovalentes biespecificos que pueden unirse a gpa33 y cd3, y pueden tener un dominio a albumina adicional o un dominio fc adicional; polinucleotido que los codifica; celula huesped; composicion farmaceutica que los comprende; y sus usos para tratar cancer.

Info

Publication number
CL2016000363A1
CL2016000363A1 CL2016000363A CL2016000363A CL2016000363A1 CL 2016000363 A1 CL2016000363 A1 CL 2016000363A1 CL 2016000363 A CL2016000363 A CL 2016000363A CL 2016000363 A CL2016000363 A CL 2016000363A CL 2016000363 A1 CL2016000363 A1 CL 2016000363A1
Authority
CL
Chile
Prior art keywords
additional
domain
gpa33
polynucleotide
encodes
Prior art date
Application number
CL2016000363A
Other languages
English (en)
Spanish (es)
Inventor
Leslie S Johnson
Francine Zhifen Chen
Ezio Bonvini
Paul A Moore
Kalpana Shah
Jonathan Li
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of CL2016000363A1 publication Critical patent/CL2016000363A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2016000363A 2013-08-23 2016-02-17 Diacuerpos monovalentes biespecificos que pueden unirse a gpa33 y cd3, y pueden tener un dominio a albumina adicional o un dominio fc adicional; polinucleotido que los codifica; celula huesped; composicion farmaceutica que los comprende; y sus usos para tratar cancer. CL2016000363A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361869528P 2013-08-23 2013-08-23
US201361907691P 2013-11-22 2013-11-22
EP13198859.4A EP2840091A1 (en) 2013-08-23 2013-12-20 Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof

Publications (1)

Publication Number Publication Date
CL2016000363A1 true CL2016000363A1 (es) 2016-10-28

Family

ID=49882883

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000363A CL2016000363A1 (es) 2013-08-23 2016-02-17 Diacuerpos monovalentes biespecificos que pueden unirse a gpa33 y cd3, y pueden tener un dominio a albumina adicional o un dominio fc adicional; polinucleotido que los codifica; celula huesped; composicion farmaceutica que los comprende; y sus usos para tratar cancer.

Country Status (24)

Country Link
US (2) US9932400B2 (OSRAM)
EP (2) EP2840091A1 (OSRAM)
JP (1) JP6581985B2 (OSRAM)
KR (1) KR102269584B1 (OSRAM)
CN (1) CN105658235B (OSRAM)
AP (1) AP2016009082A0 (OSRAM)
AU (1) AU2014308907B2 (OSRAM)
BR (1) BR112016003369A2 (OSRAM)
CA (1) CA2920117C (OSRAM)
CL (1) CL2016000363A1 (OSRAM)
CR (1) CR20160090A (OSRAM)
EA (1) EA036236B1 (OSRAM)
ES (1) ES2827226T3 (OSRAM)
GE (1) GEP20197033B (OSRAM)
IL (1) IL244238B (OSRAM)
MX (1) MX373382B (OSRAM)
MY (1) MY179866A (OSRAM)
PE (1) PE20160193A1 (OSRAM)
PH (1) PH12016500291B1 (OSRAM)
SG (1) SG11201601270WA (OSRAM)
TN (1) TN2016000052A1 (OSRAM)
TW (1) TWI675845B (OSRAM)
UA (1) UA119329C2 (OSRAM)
WO (1) WO2015026894A2 (OSRAM)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11434302B2 (en) 2016-02-03 2022-09-06 Amgen Research (Munich) Gmbh Bispecific T cell engaging antibody constructs
US11447567B2 (en) 2015-07-31 2022-09-20 Amgen Research (Munich) Gmbh Antibody constructs for FLT3 and CD3
US11884720B2 (en) 2015-07-31 2024-01-30 Amgen Research (Munich) Gmbh Antibody constructs for MSLN and CD3
US12428491B2 (en) 2016-02-03 2025-09-30 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
AR101997A1 (es) 2014-09-26 2017-01-25 Macrogenics Inc Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
US11071783B2 (en) 2015-03-19 2021-07-27 Duke University HIV-1 neutralizing antibodies and uses thereof
EP3271022A4 (en) 2015-03-19 2018-10-31 Duke University Hiv-1 neutralizing antibodies and uses thereof
US10450368B2 (en) 2015-03-19 2019-10-22 Duke University HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)
US10344077B2 (en) 2015-03-19 2019-07-09 Duke University HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3310811B1 (en) * 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
SMT202100527T1 (it) * 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
IL258759B2 (en) 2015-11-03 2023-04-01 Ambrx Inc Anti-cd3-folate conjugates and their uses
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MA55746A (fr) 2016-01-21 2022-03-02 Novartis Ag Molécules multispécifiques ciblant cll-1
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
CN107556387A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
WO2018053328A1 (en) * 2016-09-16 2018-03-22 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
CN107915776B (zh) * 2016-10-11 2021-05-14 康梦实 双特异性抗体fitc×cd3及其制备方法和应用
BR112019011277A2 (pt) 2016-12-02 2019-10-22 University Of Southern California polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
EP3558368B1 (en) 2016-12-23 2025-11-12 MacroGenics, Inc. Adam9-binding molecules, and methods of use thereof
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
IL269826B1 (en) 2017-04-11 2025-09-01 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN108728464A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达抗hiv双特异性抗体的微环dna载体及其制备方法和应用
JP7303802B2 (ja) * 2017-09-23 2023-07-05 メモリアル スローン ケタリング キャンサー センター Ａ３３抗体組成物および放射性免疫療法におけるその使用方法
SG11202005557TA (en) * 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
JP7724061B2 (ja) * 2018-04-11 2025-08-15 インヒブルクス バイオサイエンシズ インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
CN112243444A (zh) * 2018-06-08 2021-01-19 豪夫迈·罗氏有限公司 具有减少的翻译后修饰的肽接头
AU2019286396A1 (en) 2018-06-14 2020-12-17 Bioatla, Inc. Multi-specific antibody constructs
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
CN113166263A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 Dll3单域抗体及其治疗性组合物
US20220281998A1 (en) * 2019-08-28 2022-09-08 Azusapharma Sciences, Inc. Bifidobacterium spp. expressing and secreting diabody-type bsab
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
EP4240766A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
JP7402381B2 (ja) 2020-11-04 2023-12-20 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
AU2021381768A1 (en) * 2020-11-18 2023-06-22 Memorial Sloan Kettering Cancer Center Anti-gpa33 multi-specific antibodies and uses thereof
JP2023546368A (ja) 2021-05-14 2023-11-02 ジェネンテック， インコーポレイテッド モスネツズマブおよびポラツズマブベドチンを用いたｃｄ２０陽性増殖性障害の処置のための方法

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4752601A (en) 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US20030229208A1 (en) * 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US5364930A (en) 1990-10-16 1994-11-15 Northwestern University Synthetic C1q peptide fragments
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
DE69232706T2 (de) 1991-05-01 2002-11-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Rockville Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0682710B1 (en) 1993-02-10 2003-10-29 Unilever Plc Isolation process using immobilized proteins with specific binding capacities
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
EP0711303B2 (en) 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
CA2190101A1 (en) 1994-05-13 1995-11-23 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
AU4755696A (en) 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JP2000507912A (ja) 1995-08-31 2000-06-27 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 作用剤の徐放性組成物
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO1997025425A1 (en) * 1996-01-08 1997-07-17 Genentech, Inc. Wsx receptor and ligands
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5942328A (en) 1996-02-29 1999-08-24 International Business Machines Corporation Low dielectric constant amorphous fluorinated carbon and method of preparation
JP2000506165A (ja) 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6025485A (en) 1997-02-14 2000-02-15 Arcaris, Inc. Methods and compositions for peptide libraries displayed on light-emitting scaffolds
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
PL199659B1 (pl) 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
US6455263B2 (en) 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
SE9802213D0 (sv) 1998-06-18 1998-06-18 Amersham Pharm Biotech Ab A method for the removal/purification of serum albumins and means for use in the method
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US7315786B2 (en) 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
DE19937264A1 (de) 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
CN1423700A (zh) 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
CA2438628A1 (en) * 2001-02-19 2002-08-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Artificial proteins with reduced immunogenicity
EP1497318A4 (en) 2001-04-18 2006-03-01 Dyax Corp BINDING MOLECULES FOR FC ZONE POLYPEPTIDES
EP2316485A1 (en) 2001-10-12 2011-05-04 Schering Corporation Use of bispecific antibodies to regulate immune responses
WO2003033666A2 (en) 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
US20050142539A1 (en) 2002-01-14 2005-06-30 William Herman Targeted ligands
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
JP2006506954A (ja) 2002-04-29 2006-03-02 ゲンパト７７ ファーマコジェネティクス エージー Ｔｃｒ及びｔｉｒｃ７に結合する新規な抗体、並びに治療及び診断におけるその使用
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
PT1706424E (pt) 2004-01-12 2009-10-01 Applied Molecular Evolution Variantes da região fc
CA2563379A1 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
WO2005097202A2 (en) 2004-04-06 2005-10-20 Affibody Ab Use of serum albumin binding peptides conjugates for the preparation of a medicament
AU2005247301B2 (en) 2004-04-16 2011-08-18 Macrogenics, Inc. FCγRIIB-specific antibodies and methods of use thereof
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
US7432419B2 (en) 2004-05-14 2008-10-07 Los Alamos National Security, Llc Compositions and methods for the treatment of Pierce's disease
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US20060193849A1 (en) 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2010080538A1 (en) 2008-12-19 2010-07-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2573114B1 (en) 2005-08-10 2016-03-30 MacroGenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1820513A1 (en) * 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
EP2272977A1 (en) * 2009-07-08 2011-01-12 Universite Libre De Bruxelles Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome
CA2776385C (en) 2009-10-07 2019-04-09 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
EP2601218A4 (en) 2010-08-03 2015-02-18 Abbvie Inc VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
PL2606064T3 (pl) * 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
RU2013125479A (ru) 2010-11-02 2014-12-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
AR083705A1 (es) 2010-11-04 2013-03-13 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MY163368A (en) 2010-12-21 2017-09-15 Abbvie Inc Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2714079B2 (en) 2011-05-21 2019-08-28 MacroGenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
EA033677B1 (ru) 2011-05-21 2019-11-15 Macrogenics Inc Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447567B2 (en) 2015-07-31 2022-09-20 Amgen Research (Munich) Gmbh Antibody constructs for FLT3 and CD3
US11884720B2 (en) 2015-07-31 2024-01-30 Amgen Research (Munich) Gmbh Antibody constructs for MSLN and CD3
US11434302B2 (en) 2016-02-03 2022-09-06 Amgen Research (Munich) Gmbh Bispecific T cell engaging antibody constructs
US12428491B2 (en) 2016-02-03 2025-09-30 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs

Also Published As

Publication number Publication date
US20180118824A1 (en) 2018-05-03
US20160222105A1 (en) 2016-08-04
TWI675845B (zh) 2019-11-01
AP2016009082A0 (en) 2016-03-31
BR112016003369A2 (pt) 2017-11-21
IL244238B (en) 2019-12-31
PE20160193A1 (es) 2016-04-21
IL244238A0 (en) 2016-04-21
US10858430B2 (en) 2020-12-08
AU2014308907A1 (en) 2016-02-25
JP6581985B2 (ja) 2019-09-25
EA036236B1 (ru) 2020-10-16
WO2015026894A3 (en) 2015-04-16
UA119329C2 (uk) 2019-06-10
EA201690447A1 (ru) 2016-08-31
CA2920117A1 (en) 2015-02-26
JP2017504578A (ja) 2017-02-09
EP2840091A1 (en) 2015-02-25
CR20160090A (es) 2016-07-13
EP3035956B1 (en) 2020-07-22
EP3035956A2 (en) 2016-06-29
TN2016000052A1 (en) 2017-07-05
KR102269584B1 (ko) 2021-06-28
PH12016500291A1 (en) 2016-05-02
PH12016500291B1 (en) 2016-05-02
SG11201601270WA (en) 2016-03-30
AU2014308907B2 (en) 2019-05-16
CA2920117C (en) 2022-05-10
TW201605895A (zh) 2016-02-16
GEP20197033B (en) 2019-10-25
MX373382B (es) 2020-05-12
ES2827226T3 (es) 2021-05-20
EP3035956A4 (en) 2017-05-03
KR20160045135A (ko) 2016-04-26
CN105658235B (zh) 2020-09-11
MX2016001738A (es) 2016-05-31
MY179866A (en) 2020-11-18
WO2015026894A2 (en) 2015-02-26
NZ716697A (en) 2021-11-26
CN105658235A (zh) 2016-06-08
US9932400B2 (en) 2018-04-03
HK1226000A1 (en) 2017-09-22

Similar Documents

Publication Publication Date Title
CL2016000363A1 (es) Diacuerpos monovalentes biespecificos que pueden unirse a gpa33 y cd3, y pueden tener un dominio a albumina adicional o un dominio fc adicional; polinucleotido que los codifica; celula huesped; composicion farmaceutica que los comprende; y sus usos para tratar cancer.
CL2016000293A1 (es) Diacuerpos fc monovalentes biespecíficos que son capaces de unirse a cd32b y cd79b y usos de los mismos
MX2018005551A (es) Anticuerpos que se unen especificamente a pd-1, y sus usos.
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
PL3328889T3 (pl) Konstrukty przeciwciała dwuswoistego wiążące DLL3 i CD3
ECSP17040521A (es) Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales
NI201700037A (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
CL2016003050A1 (es) Moléculas de unión tri-específicas que se unen específicamente a varios antígenos de cáncer y métodos de uso de los mismos.
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
BR112016022385A2 (pt) anticorpos específicos que se ligam a cd38 e cd3
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
CL2016000777A1 (es) Biomarcadores de cáncer y usos de los mismos
MX375953B (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
PL3763387T3 (pl) Kompozycje zawierające przeciwciała anty-ceacam1 i anty-pd do terapii nowotworu
CL2016001147A1 (es) Anticuerpos específicos para fcrn.
LT3371165T (lt) Btk inhibitorius, naudojamas vėžiui gydyti
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
DK3200822T3 (da) Bindingsmolekyler, i særdeleshed antistoffer, der binder til l1cam (cd171)
DOP2016000105A (es) Anticuerpos anti-ccl17.
BR112015028732A2 (pt) método, e um ou mais meios legíveis por computador não transitórios tangíveis
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.
DK3071192T3 (da) Curcuphenolforbindelse til anvendelse i behandling af cancer
DK3317300T3 (da) Bispecifikke antistoffer til anvendelse i kræftimmunterapi
DK2958590T3 (da) Bispecifikt antistof, der binder til naaladl2 og cd3, til anvendelse som et terapeutisk middel i behandling af prostatacancer
ES1080455Y (es) Dispositivo laminador para placas acrilicas